株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

鬱血性心不全(心不全):パイプライン製品の分析

Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2017

発行 Global Markets Direct 商品コード 245973
出版日 ページ情報 英文 396 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.40円で換算しております。
Back to Top
鬱血性心不全(心不全):パイプライン製品の分析 Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2017
出版日: 2017年08月08日 ページ情報: 英文 396 Pages
概要

鬱血性心不全は心不全は鬱血性心不全(CHF)としても知られています。CHFは、心臓がもはや酸素を豊富に含む血液を十分に送り出すことが出来ない状態です。症状には、咳、疲労感、虚弱、脱力感、食欲不振、肝臓または腹部の腫れ(肥大)、足・足首の腫れ、および体重増加などがあります。発病の要因には、高血圧、糖尿病、睡眠時無呼吸、アルコール摂取および不整脈が含まれます。治療には、外科手術、血管拡張剤、ベータブロッカー、および利尿薬などが用いられます。

当レポートでは、世界における鬱血性心不全治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 調査範囲

鬱血性心不全(心不全)の概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

  • Amgen Inc.
  • AnGes MG, Inc.
  • Araim Pharmaceuticals, Inc.
  • ARCA biopharma, Inc.
  • Ascelegen Therapeutics, Inc.
  • Asterias Biotherapeutics, Inc.
  • Athersys, Inc.
  • Bayer AG
  • BEAT BioTherapeutics Corp.
  • BioCardia, Inc.
  • Bristol-Myers Squibb Company
  • Capricor Therapeutics, Inc.
  • Cell Therapy Limited
  • Celyad SA
  • Eli Lilly and Company
  • FibroGen, Inc.
  • GlaxoSmithKline Plc
  • Glucox Biotech AB
  • Heart Metabolics Limited
  • Hemostemix Ltd
  • Innopharmax Inc.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Juventas Therapeutics, Inc.
  • La Jolla Pharmaceutical Company
  • Laboratoires Pierre Fabre SA
  • Lead Discovery Center GmbH
  • Lee's Pharmaceutical Holdings Limited
  • Les Laboratoires Servier SAS
  • Lonestar Heart, Inc.
  • Mast Therapeutics, Inc.
  • Merck & Co., Inc.
  • Mesoblast Limited
  • miRagen Therapeutics, Inc.
  • MorphoSys AG
  • NanoCor Therapeutics, Inc.
  • Neurocrine Biosciences, Inc.
  • Novartis AG
  • Nuo Therapeutics, Inc.
  • 小野薬品工業
  • Palatin Technologies, Inc.
  • Pfizer Inc.
  • PharmaIN Corporation
  • PhaseBio Pharmaceuticals, Inc.
  • Pluristem Therapeutics Inc.
  • Quantum Genomics SA
  • Recardio GmbH
  • RedHill Biopharma Ltd.
  • Renova Therapeutics Inc
  • scPharmaceuticals Inc
  • Stealth BioTherapeutics Inc.
  • Stemedica Cell Technologies, Inc.
  • Target Heart Biotec Srl
  • Theravance Biopharma, Inc.
  • TiGenix NV
  • Torrent Pharmaceuticals Limited
  • Trevena, Inc.
  • U.S. Stem Cell, Inc.
  • Vichem Chemie Research Ltd.
  • Vicore Pharma AB
  • Zensun (Shanghai) Sci & Tech Co., Ltd.

治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9607IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2017, provides an overview of the Congestive Heart Failure (Heart Failure) (Cardiovascular) pipeline landscape.

Heart failure is also known as congestive heart failure (CHF). CHF is a condition in which the heart is no longer able to pump out enough oxygen-rich blood. Symptoms include cough, fatigue, weakness, faintness, loss of appetite, swollen (enlarged) liver or abdomen, swollen feet and ankles and weight gain. The predisposing factors include high blood pressure, diabetes, sleep apnea, alcohol use and irregular heartbeats. Treatment includes surgery, vasodilator, beta blockers and diuretics.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Congestive Heart Failure (Heart Failure) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Congestive Heart Failure (Heart Failure) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Congestive Heart Failure (Heart Failure) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 19, 27, 17, 2, 43, 11 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 19 and 8 molecules, respectively.

Congestive Heart Failure (Heart Failure) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Congestive Heart Failure (Heart Failure) (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Congestive Heart Failure (Heart Failure) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Congestive Heart Failure (Heart Failure) (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Congestive Heart Failure (Heart Failure) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Congestive Heart Failure (Heart Failure) (Cardiovascular)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Congestive Heart Failure (Heart Failure) (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Congestive Heart Failure (Heart Failure) (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Congestive Heart Failure (Heart Failure) - Overview
  • Congestive Heart Failure (Heart Failure) - Therapeutics Development
  • Congestive Heart Failure (Heart Failure) - Therapeutics Assessment
  • Congestive Heart Failure (Heart Failure) - Companies Involved in Therapeutics Development
  • Congestive Heart Failure (Heart Failure) - Drug Profiles
  • Congestive Heart Failure (Heart Failure) - Dormant Projects
  • Congestive Heart Failure (Heart Failure) - Discontinued Products
  • Congestive Heart Failure (Heart Failure) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Congestive Heart Failure (Heart Failure), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..4), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..5), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..6), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Acorda Therapeutics Inc, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Amgen Inc, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by AnGes MG Inc, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Araim Pharmaceuticals Inc, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Arbor Pharmaceuticals LLC, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Ascendia Pharmaceuticals LLC, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by AstraZeneca Plc, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Athersys Inc, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Bayer AG, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by BEAT BioTherapeutics Corp, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by BioCardia Inc, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by BlueRock Therapeutics, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Boehringer Ingelheim GmbH, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Bristol-Myers Squibb Company, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by C&C BioPharma LLC, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Capricor Therapeutics Inc, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Celixir Ltd, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Celyad SA, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Egalet Corp, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by FibroGen Inc, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Galenica Ltd, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by GlaxoSmithKline Plc, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Heart Metabolics Ltd, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Hemostemix Ltd, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Immunwork Inc, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Innopharmax Inc, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Johnson & Johnson, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Juventas Therapeutics Inc, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by La Jolla Pharmaceutical Company, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Lead Discovery Center GmbH, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Les Laboratoires Servier SAS, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Lonestar Heart Inc, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Madeleine Pharmaceuticals Inc, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Merck & Co Inc, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Mesoblast Ltd, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by MorphoSys AG, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by N-Gene Research Laboratories Inc, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by NanoCor Therapeutics Inc, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Neurocrine Biosciences Inc, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Novartis AG, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Nuo Therapeutics Inc, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Orion Oyj, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Palatin Technologies Inc, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Paradigm Biopharmaceuticals Ltd, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by PharmaIN Corp, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by PhaseBio Pharmaceuticals Inc, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Quantum Genomics SA, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Recardio GmbH, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Renova Therapeutics Inc, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Sarfez Pharmaceuticals Inc, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Savara Inc, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by scPharmaceuticals Inc, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Stealth BioTherapeutics Inc, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Stemedica Cell Technologies Inc, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Theravance Biopharma Inc, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by TiGenix NV, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Torrent Pharmaceuticals Ltd, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Trevena Inc, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by U.S. Stem Cell Inc, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Vicore Pharma AB, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by XyloCor Therapeutics Inc, H2 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Zensun (Shanghai) Sci & Tech Co Ltd, H2 2017
  • Congestive Heart Failure (Heart Failure) - Dormant Projects, H2 2017
  • Congestive Heart Failure (Heart Failure) - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Congestive Heart Failure (Heart Failure) - Dormant Projects, H2 2017 (Contd..2), H2 2017
  • Congestive Heart Failure (Heart Failure) - Dormant Projects, H2 2017 (Contd..3), H2 2017
  • Congestive Heart Failure (Heart Failure) - Dormant Projects, H2 2017 (Contd..4), H2 2017
  • Congestive Heart Failure (Heart Failure) - Dormant Projects, H2 2017 (Contd..5), H2 2017
  • Congestive Heart Failure (Heart Failure) - Discontinued Products, H2 2017
  • Congestive Heart Failure (Heart Failure) - Discontinued Products, H2 2017 (Contd..1), H2 2017

List of Figures

  • Number of Products under Development for Congestive Heart Failure (Heart Failure), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Top 10 Molecule Types, H2 2017
  • Number of Products by Stage and Top 10 Molecule Types, H2 2017
Back to Top